Latest Parkinsons Disease News

Rare, incurable brain disease patients improve after UF-engineered gene therapyUsing gene transfer techniques pioneered by University of Florida researchers, Taiwanese doctors have restored some movement in four children bedridden with a rare, life-threatening neurological disease. The first-in-humans achievement may also be he...

Locating ground zero(European Molecular Biology Laboratory) Scientists at EMBL Heidelberg have discovered exactly how cells called microglia detect the site of brain injury - a finding that paves the way for new medical approaches to conditions where microglia's ability...

Immune cells "sculpt" circuits in the brain -- by eating away excess connectionsFindings offer a fresh look at developmental and degenerative brain diseases BOSTON, May 23, 2012 /PRNewswire-USNewswire/ -- We're born with our brains prewired, but as information comes in from our environment, this circuitry is updated. A study from Boston Children's Hospital provides a new glimpse of how this happens: Brain cells known as microglia, tuned into the crosstalk between ne...

Molecular 'on-off' switch for Parkinson's disease discovered(Medical Xpress) -- Scientists at the Medical Research Council (MRC) Protein Phosphorylation Unit at the University of Dundee have discovered a new molecular switch that acts to protect the brain from developing Parkinson's disease.

Study supports urate protection against Parkinson's disease, hints at novel mechanism(Massachusetts General Hospital) Use of the antioxidant urate to protect against the neurodegeneration caused by Parkinson's disease appears to rely on more than urate's ability to protect against oxidative damage. In the May issue of the open-acces...

NYSE/NASDAQ: Best Buy, JPMorgan Chase, General Mills, Facebook and moreElectronics retailer Best Buy (NYSE:BBY) Tuesday posted fiscal first-quarter earnings that beat analyst estimates thanks to high demand for smartphones. For the period ended May 5, Best Buy said profit fell to $158 million, or 46 cents per share, com...

FDA turns down Chelsea Therapeutics’ Northera drug, shares tumbleChelsea Therapeutics (NASDAQ:CHTP) said Tuesday that the U.S. Food and Drug Administration (FDA) has rejected its hypotension capsule Northera and sought an additional trial to support the efficacy of the drug.The drug, known generically as droxidopa...

News: Genetic predictor of Parkinson%u2019s disease progressionResearch published in PLoS One suggests that Parkinson’s disease patients with a particular gene variant are likely to experience faster decline in motor function. Parkinson’s disease is characterised by progressive deterioration...

Genetic predictor of Parkinson's disease progressionResearch published in PLoS One suggests that Parkinson’s disease patients with a particular gene variant are likely to experience faster decline in motor function. Parkinson’s disease is characterised by progressive deterioration...

News: Genetic predictor of Parkinson's disease progressionResearch published in PLoS One suggests that Parkinson’s disease patients with a particular gene variant are likely to experience faster decline in motor function. Parkinson’s disease is characterised by progressive deterioration...

Enginasion Partners with TransCytos to Develop Breakthrough ‘Transfection’ Technology for Genetic Engineering ApplicationsTransCytos: NEVER BEEN DONE BEFORE Enginasion and TransCytos announced today that their collaboration has resulted in a prototype ‘transfection’ technology that is designed to have a dramatic and positive impact on the drug-research industry. Enginasion’s product development partner, TransCytos, is developing a novel t...

CORRECTING and REPLACING Douglas and Sandra Bergeron Fund Endowment at Georgetown University Medical CenterThe second and seventh graphs as well as the caption of release should read: Center for Brain Plasticity and Recovery (sted Center for Brain Plasticity and Repair). A $1.25 million gift to Georgetown University Medical Center in George Bergeron's memory by his son, Doug, and daughter-in-law, Sandra, will launch the Center for Brain Plasticity and Recovery and fund...

Douglas and Sandra Bergeron Fund Endowment at Georgetown University Medical CenterDouglas and Sandra Bergeron today announced they have gifted $1.25 million to the Georgetown University Medical Center (GMUC) to support cutting-edge biomedical research in the neurosciences and celebrate George Bergeron, who lived with multiple sclerosis for over 30 years. A $1.25 million gift to Georgetown University Medical Center in George Bergeron's mem...

Michael J. Fox Looks Past Stem Cells in Search For Parkinson’s CureMichael J. Fox, whose turn from Parkinson’s disease patient to scientific crusader made him one of the country’s most visible advocates for stem cell research, now believes the controversial therapy may not ultimately yield a cure for his dise...

iPierian Advances Monoclonal Antibody Drug Development Programs Targeting Tau Protein and the Complement System for the Treatment of Neurodegenerative DiseasesiPierian, Inc., announced today the first development programs in its drug pipeline: monoclonal antibodies to treat neurodegenerative diseases by targeting the Tau protein and the Complement pathway. Tau protein and the Complement pathway represent central mechanisms driving an array of neurodegenerative diseases, which will allow the company to pursue a s...

The Michael J. Fox Foundation Announces Second Quarter Participants in Partnering Program Between Awardees and IndustryNEW YORK, May 21, 2012 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) has announced second-quarter 2012 participants in its Partnering Program. The Partnering Program proactively showcases promising research results from the MJFF portfolio — targeting funders who may wish to invest in their continued development. "The challenges of translating basic discoveries into new the...

European Medical Marijuana product Sativex is challenged by North America’s New Cannabis Pill Idrasil, Says DoobonsIdrasil, a full-spectrum cannabinoid pill, satisfies the medical community with its standardized 25 mg tablet and changes the way patients and physicians view medical marijuana. San Francisco, CA (PRWEB) May 19, 2012 Doobons.com and Idrasil are discovering that the groundbreaking new medical marijuana pill, Idrasil, is in high demand by patients all over the world who are looking for the benefits...

Ceregene announces new data from CERE-120 clinical trial on Parkinson'sCeregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delive...

Deals of the Week Ponders The Complications

Sometimes, a pharma partnership is a prelude to a buyout deal. Other times, as some lovelorn users of one newsworthy social network like to say, it’s complicated. For GlaxoSmithKline, its relationships with three different companies show how one ki...

Gene Therapy Helps Children With Rare, Incurable Brain DiseaseUsing gene transfer techniques pioneered by University of Florida faculty, Taiwanese doctors have restored some movement in four children bedridden with a rare, life-threatening neurological disease. The first-in-humans achievement may also be helpfu...

Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced ...First Evidence for Long Term, Biologically Active Protein Expression in the Human Brain by Gene Therapy

Lonza and Avalanche Biotechnologies in gene therapy viral vectors manufacturing collaborationLonza and Avalanche Biotechnologies, Inc, a specialist in long-term protein delivery for ocular diseases, have formed a manufacturing collaboration focused on process development and scale-up for the manufacturing of adeno-associated viral (AAV) vect...

Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)SAN DIEGO, May 17, 2012 /PRNewswire/ -- Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with...

Cynapsus Therapeutics Inc.: Cynapsus Therapeutics Retains US Investor Relations Firm TORONTO -- (Marketwire) -- 05/17/12 -- Cynapsus Therapeutics Inc. ("Cynapsus") (http://www.cynapsus.ca) (TSX-V: CTH) today announced that it has retained JSDC, Inc. ("JSDC") to provide US-based investor relations services for the Company. Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease....

Potential To Predict Parkinson's Disease Via Colonoscopy Or Flexible SigmoidoscopyTwo studies by neurological researchers at Rush University Medical Center suggest that, in the future, colonic tissue obtained during either colonoscopy or flexible sigmoidoscopy may be used to predict who will develop Parkinson's disease, a neurodeg...

0 1 2 3 4 ›»

buy Parkinsons Disease market research data and corporate reports now Advertisement